Osiris Completes Enrollment in Stem Cell Trial for Type 1 Diabetes

UPDATE 2-Novo hits high as FDA approves diabetes drug
(Refiles to delete redundant paragraph

Read more on Reuters via Yahoo! Asia News

Freedom Meditech Presents Data Showing Benefits of Non-Invasive Diabetes Screening and Glucose Monitoring in the Eye …
LONDON—-People with diabetes or who are at risk of developing the disease – now estimated at over 400 million globally – could reduce complications, improve quality of life and reduce healthcare costs by using new non-invasive technology to screen for and monitor the illness, according to a presentation by Freedom Meditech at the 6th Annual Diabetes and Diabetic Retinopathy Conference in …

Read more on Business Wire via Yahoo! Finance

Saturday, January 30
The Diabetes Foundation of Mississippi’s Super Conference starts at 7 a.m. at the Marriott Hotel (200 E. Amite St.). Cost includes all sessions and lunch. Space is limited. $25, $40 for two, $10 children 12 and under; call 601-957-7878 or 877-DFM-CURE. …

Read more on Jackson Free Press

Intense blood sugar treatment risky
Aggressively treating some people with Type 2 diabetes to lower their blood sugar levels may increase the risk of premature death, researchers have found.

Read more on CBC.ca

Osiris Completes Enrollment in Stem Cell Trial for Type 1 Diabetes
COLUMBIA, Md.—-Osiris Therapeutics, Inc. today announced that it has achieved a $750,000 milestone payment from the Juvenile Diabetes Research Foundation for completing enrollment in a Phase II clinical trial evaluating Prochymal, an adult mesenchymal stem cell therapy, as a treatment for patients recently diagnosed with type 1 diabetes.

Read more on Business Wire via Yahoo! Finance